Though Gilead Sciences leads the group of companies developing immunotherapies that target the cancer protein CD47, Pfizer contends that molecules it is getting through the Trillium Therapeutics acquisition have safety and efficacy advantages that could make them the best in this emerging drug class.
The drugmaker's equity investment is just the latest in a string of large biopharma companies making moves into the emerging space of cancer immunotherapy drugs targeting CD47. AbbVie announced a $2 billion deal with I-Mab last week, while Gilead spent $4.9 billion to buy Forty Seven in March.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.